Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes

European Journal of Pharmacology

Volumn 376, Issue 1-2, 1999, Pages 189-201

  Cheng, Jianhua ^b   Niwa, Ryoko ^a   Kamiya, Kaichiro ^a   Toyama, Junji ^c   Kodama, Itsuo ^a  

^a Department of Circulation Div Reg Organ Funct Res I ^*  (Japan)

^b TONGJI UNIVERSITY   (China)

^c Aichi Prefectural Owari Hospital   (Japan)

Author keywords

Adrenoceptor antagonist; Frequency dependence reverse; Membrane current; Membrane potential; Ventricle, rabbit

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; CARVEDILOL; NISOLDIPINE; RESERPINE; TETRODOTOXIN;

ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; DEPOLARIZATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART VENTRICLE WALL; MEMBRANE CURRENT; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT;

EID: 0032988575     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00368-4     Document Type: Article

References (50)

1. Amiodarone Trials Meta-Analysis Investigators Effects of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure. Lancet. 350:1997;1417-1424.
2. Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation. 96:1997;183-191.
3. Bigger J.T. Jr. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation. 75:1987;28-35.
4. Bril A., Tomasi V., Laville M.-P. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to ischemia and reperfusion. Pharmacol. Commun. 5:1995;281-300.
5. MOCHA Investigators, Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narabara K.A., Ingersoll H., Krueger S., Young S., Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
6. Brunvand H., Frlyland L., Hexeberg E., Rynning S.E., Berge R.K., Grong K. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury. Eur. J. Pharmacol. 314:1996;99-107.
7. sK channels by chromanol 293B. Pflügers Arch. 432:1996;1094-1096.
8. + current in cardiac myocytes by dofetilide. J. Pharmacol. Exp. Ther. 262:1992;809-817.
9. Chakki C.S., Gherghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am. Heart J. 109:1985;497-504.
10. + current in rabbit ventricular myocytes. Cardiovasc. Res. 31:1996;963-974.
11. + current: a potential mechanism of the proarrhythmic effects of methanesulfonanilide class III agents. Cardiovasc. Res. (in press).
12. Cooperative Studies Group, Cohn J.N., V-HeFT V.A. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 87:1993;5-16. Suppl. VI.
13. Dunn C.J., Lea A.P., Wagstaff A.J. Carvedilol: a reappraisal of its pharmacological properties and therapeutical use in cardiovascular disorders. Drugs. 54:1997;161-185.
14. Esler M., Kaye D., Lambert G., Esler D., Jennings G. Adrenergic nervous system in heart failure. Am. J. Cardiol. 80(11A):1997;7L-14L.
15. Fedida D., Giles W.R. Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. J. Physiol. 442:1991;191-209.
16. Giles W.R., Imaizumi Y. Comparison of potassium currents in rabbit atrial and ventricular cells. J. Physiol. 405:1988;123-145.
17. Gwilt M., Arrowsmith J.E., Blackburn K.J., Burges R.A., Cross P.E., Dalrymple H.W., Higgins A.J. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther. 256:1991;318-324.
18. Hafner D., Berger F., Borchard U., Kullmann A., Scherlitz A. Electrophysiological characterization of the class III activity of sotalol and its enantiomers: new interpretation of use-dependent effects. Drug Res. 38:1988;231-236.
19. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflügers Arch. 391:1981;85-100.
20. Hattori Y., Nakaya H., Endou M., Nakao Y., Kanno M. Vascular effects of carvedilol, a new β-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. J. Cardiovasc. Pharmacol. 13:1989;572-579.
21. Hiraoka M., Kawano S. Calcium-sensitive and insensitive transient outward current in rabbit ventricular myocytes. J. Physiol. 410:1989;187-212.
22. Hoher M., Friedrich M., Sommer T., Marten A., Ehmer B., Hombach V., Hirche H. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs (in German). Z. Kardiol. 78:1989;7-15. Suppl. 3.
23. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
24. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am. J. Cardiol. 65:1990;421-481.
25. Kodama I., Suzuki R., Kamiya K., Iwata H., Toyama J. Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br. J. Pharmacol. 107:1992;502-509.
26. The Intravenous Amiodarone Multicenter Investigators Group, Kowey P.R., Levine J.H., Herre J.M., Pacifico A., Lindsay B.D., Plumb V.J., Janosik D.L., Kopelman H.A., Scheinman M.M. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachyarrhythmia of fibrillation. Circulation. 92:1995;3255-3263.
27. McPhillips J.J., Schwemer G.T., Scott D.I., Zinny M., Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. Drugs. 36:1988;82-91. Suppl. 6.
28. McTavish D., Campoli-Richards D., Sorkin E.M. Carvedilol: a review of its pharmacological and pharmacokinetic properties, and therapeutic efficacy. Drugs. 45:1993;232-258.
29. Morgan T.O., Anderson A., Cripps J., Adam W. Pharmacokinetics of carvedilol in older and younger patients. J. Human Hypertens. 4:1990;709-715.
30. Moser M., Frishman W. Results of therapy with carvedilol, a β-blocker with antioxidant properties, in hypertensive patients. Am. J. Hypertens. 11:1998;15S-22S.
31. Nichols A.J., Sulpizio A.C., Ashton D.J., Hieble J.P., Ruffolo R.R. Jr. In vitro pharmacologic profile of the novel β-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology. 39:1989;327-336.
32. Nichols A.J., Gellai M., Ruffolo R.R. Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam. Clin. Pharmacol. 5:1991;25-38.
33. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation. 72:1985;681-685.
34. US Carvedilol Heart Failure Study Group, Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New. Engl. J. Med. 334:1996;1349-1355.
35. Pratt C.M., Eaton T., Francis M., Woolbert S., Mahmarian J., Roberts R., Young J.B. The inverse relationship between baseline left ventricular ejection fraction and outcome from antiarrhythmic therapy: a dangerous imbalance in risk-benefit ratio. Am. Heart J. 118:1989;433-440.
36. Ruffolo R.R. Jr., Feuerstein G.Z. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc. Drugs Ther. 11:1997;247-256. Suppl. 1.
37. Ruffolo R.R. Jr., Gellai M., Hieble J.P., Willette R.N., Nichols A.J. The pharmacology of carvedilol. Eur. J. Pharmacol. 38:1990;S82-S88.
38. Ruffolo R.R. Jr., Sauermelch C.F. Jr., Willette R.N. Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation. Eur. J. Clin. Pharmacol. 38:1990;S112-S114.
39. Ks. Am. J. Physiol. 271:1996;H2477-H2489.
40. + current: differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96:1990;195-215.
41. The Intravenous Amiodarone Multicenter Investigators Group, Scheinman M.M., Levine J.H., Cannom D.S., Friehling T., Kopelman H.A., Chilson D.A., Platia E.V., Wilber D.J., Kowey P.R. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation. 92:1995;3264-3272.
42. Senior R., Müller-Beckmann B., DasGupta P., van der Does R., Lahiri A. Effects of carvedilol on ventricular arrhythmias. J. Cardiovasc. Pharmacol. 19:1992;S117-S121.
43. Shimoni Y., Clark R.B., Giles W.R. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. J. Physiol. 448:1992;709-727.
44. Singh B.N. Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm. Am. J. Cardiol. 81(6A):1998;3D-13D.
45. K blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J. Cardiovasc. Pharmacol. 16:1990;401-410.
46. + current. Circulation. 96:1997;3696-3703.
47. Underwood R.D., Sra J., Akhtar M. Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction. Clin. Cardiol. 20:1997;753-758.
48. Wettwer E., Scholtysik G., Schaad A., Himmel H., Ravens U. Effects of new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J. Cardiovasc. Pharmacol. 17:1991;480-487.
49. Wright D.J., Cooke G.A., Tan L.B. Intractable recurrent ventricular tachycardia in dilated cardiomyopathy controlled by a vasodilating β blocker. Heart. 77:1997;581-582.
50. Yazawa K., Kaibara M., Ohara M., Kameyama M. An improved method for isolating cardiac myocytes useful for patch-clamp studies. Jpn. J. Physiol. 40:1990;157-163.